ACE variants and risk of intracerebral hemorrhage recurrence in amyloid angiopathy

Neurobiology of Aging

Volumn 32, Issue 3, 2011, Pages 551.e13-551.e22

  Domingues Montanari, Sophie ^a   Hernandez Guillamon, Mar ^a   Fernandez Cadenas, Israel ^a   Mendioroz, Maite ^a   Boada, Mercè ^a,b   Munuera, Josep ^c   Rovira, Alex ^c   Maisterra, Olga ^a   Parés, Mireia ^a   Gutierrez, Maria ^a   Alvarez Sabin, José ^a   Chacón, Pilar ^c   Delgado, Pilar ^a   Montaner, Joan ^a  

^a UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^b Fundacio ACE   (Spain)

^c HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

ACE; APOE; Cerebral amyloid angiopathy; Genetics; Hypertension; Intracerebral hemorrhage; Leukoaraoisis; Microbleeds; Protein level; Stroke

Indexed keywords

ALDOSTERONE SYNTHASE; APOLIPOPROTEIN E; DIPEPTIDYL CARBOXYPEPTIDASE; ENZYME VARIANT; GELATINASE B; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; VASCULOTROPIN A;

ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CLINICAL FEATURE; ENZYME BLOOD LEVEL; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; LEUKOARAIOSIS; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK FACTOR; VASCULAR AMYLOIDOSIS;

EID: 79952901893     PISSN: 01974580     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.01.019     Document Type: Article

References (54)

1. Backstrom J.R., Lim G.P., Cullen M.J., Tokes Z.A. Matrix metalloproteinase-9 (MMP-9) is synthesized in neurons of the human hippocampus and is capable of degrading the amyloid-beta peptide (1-40). J. Neurosci 1996, 16:7910-7919.
2. Bertram L., McQueen M.B., Mullin K., Blacker D., Tanzi R.E. Systematic meta-analyses of Alzheimer disease genetic association studies: the AlzGene database. Nat. Genet 2007, 39:17-23.
3. Bizzarro A., Seripa D., Acciarri A., Matera M.G., Pilotto A., Tiziano F.D., Brahe C., Masullo C. The complex interaction between APOE promoter and AD: an Italian case-control study. Eur. J. Hum. Genet 2009, 17:938-945.
4. Chalmers K.A., Culpan D., Kehoe P.G., Wilcock G.K., Hughes A., Love S. APOE promoter, ACE1 and CYP46 polymorphisms and beta-amyloid in Alzheimer's disease. Neuroreport 2004, 15:95-98.
5. Chen Y.W., Gurol M.E., Rosand J., Viswanathan A., Rakich S.M., Groover T.R., Greenberg S.M., Smith E.E. Progression of white matter lesions and hemorrhages in cerebral amyloid angiopathy. Neurology 2006, 67:83-87.
6. Christoforidis M., Schober R., Krohn K. Genetic-morphologic association study: association between the low density lipoprotein-receptor related protein (LRP) and cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol 2005, 31:11-19.
7. Clarimon J., Bertranpetit J., Calafell F., Boada M., Tarraga L., Comas D. Association study between Alzheimer's disease and genes involved in Abeta biosynthesis, aggregation and degradation: suggestive results with BACE1. J. Neurol 2003, 250:956-961.
8. Clarimon J., Munoz F.J., Boada M., Tarraga L., Sunyer J., Bertranpetit J., Comas D. Possible increased risk for Alzheimer's disease associated with neprilysin gene. J. Neural Transm 2003, 110:651-657.
9. Eckman E.A., Adams S.K., Troendle F.J., Stodola B.A., Kahn M.A., Fauq A.H., Xiao H.D., Bernstein K.E., Eckman C.B. Regulation of steady-state beta-amyloid levels in the brain by neprilysin and endothelin-converting enzyme but not angiotensin-converting enzyme. J. Biol. Chem 2006, 281:30471-30478.
10. Fernandez-Cadenas I., Molina C.A., Alvarez-Sabin J., Ribo M., Penalba A., Ortega-Torres L., Delgado P., Quintana M., Rosell A., Montaner J. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neurosci. Lett 2006, 398:167-171.
11. Greenberg S.M., Briggs M.E., Hyman B.T., Kokoris G.J., Takis C., Kanter D.S., Kase C.S., Pessin M.S. Apolipoprotein E epsilon 4 is associated with the presence and earlier onset of hemorrhage in cerebral amyloid angiopathy. Stroke 1996, 27:1333-1337.
12. Greenberg S.M., Eng J.A., Ning M., Smith E.E., Rosand J. Hemorrhage burden predicts recurrent intracerebral hemorrhage after lobar hemorrhage. Stroke 2004, 35:1415-1420.
13. Greenberg S.M., Vonsattel J.P., Segal A.Z., Chiu R.I., Clatworthy A.E., Liao A., Hyman B.T., Rebeck G.W. Association of apolipoprotein E epsilon2 and vasculopathy in cerebral amyloid angiopathy. Neurology 1998, 50:961-965.
14. Hadjadj S., Tarnow L., Forsblom C., Kazeem G., Marre M., Groop P.H., Parving H.H., Cambien F., Tregouet D.A., Gut I.G., Theva A., Gauguier D., Farrall M., Cox R., Matsuda F., Lathrop M., Hager-Vionnet N. Association between angiotensin-converting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J. Am. Soc. Nephrol 2007, 18:1284-1291.
15. Hamaguchi T., Okino S., Sodeyama N., Itoh Y., Takahashi A., Otomo E., Matsushita M., Mizusawa H., Yamada M. Association of a polymorphism of the transforming growth factor-beta1 gene with cerebral amyloid angiopathy. J. Neurol. Neurosurg. Psychiatry 2005, 76:696-699.
16. Hanger H.C., Wilkinson T.J., Fayez-Iskander N., Sainsbury R. The risk of recurrent stroke after intracerebral haemorrhage. J. Neurol. Neurosurg. Psychiatry 2007, 78:836-840.
17. Hassan A., Lansbury A., Catto A.J., Guthrie A., Spencer J., Craven C., Grant P.J., Bamford J.M. Angiotensin converting enzyme insertion/deletion genotype is associated with leukoaraiosis in lacunar syndromes. J. Neurol. Neurosurg. Psychiatry 2002, 72:343-346.
18. Hemming M.L., Selkoe D.J. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J. Biol. Chem 2005, 280:37644-37650.
19. Hu J., Igarashi A., Kamata M., Nakagawa H. Angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide (A beta); retards A beta aggregation, deposition, fibril formation; and inhibits cytotoxicity. J. Biol. Chem 2001, 276:47863-47868.
20. Jellinger K.A. Alzheimer disease and cerebrovascular pathology: an update. J. Neural Transm 2002, 109:813-836.
21. Jenkins T.A., Chai S.Y. Effect of chronic angiotensin converting enzyme inhibition on spatial memory and anxiety-like behaviours in rats. Neurobiol. Learn. Mem 2007, 87:218-224.
22. Kauwe J.S., Wang J., Mayo K., Morris J.C., Fagan A.M., Holtzman D.M., Goate A.M. Alzheimer's disease risk variants show association with cerebrospinal fluid amyloid beta. Neurogenetics 2009, 10:13-17.
23. Kehoe P.G., Katzov H., Feuk L., Bennet A.M., Johansson B., Wiman B., de Faire U., Cairns N.J., Wilcock G.K., Brookes A.J., Blennow K., Prince J.A. Haplotypes extending across ACE are associated with Alzheimer's disease. Hum. Mol. Genet 2003, 12:859-867.
24. Kehoe P.G., Miners S., Love S. Angiotensins in Alzheimer's disease - friend or foe?. Trends Neurosci 2009, 32:619-628.
25. Kehoe P.G., Russ C., McIlory S., Williams H., Holmans P., Holmes C., Liolitsa D., Vahidassr D., Powell J., McGleenon B., Liddell M., Plomin R., Dynan K., Williams N., Neal J., Cairns N.J., Wilcock G., Passmore P., Lovestone S., Williams J., Owen M.J. Variation in DCP1, encoding ACE, is associated with susceptibility to Alzheimer disease. Nat. Genet 1999, 21:71-72.
26. Knudsen K.A., Rosand J., Karluk D., Greenberg S.M. Clinical diagnosis of cerebral amyloid angiopathy: validation of the Boston criteria. Neurology 2001, 56:537-539.
27. Lee J.M., Yin K.J., Hsin I., Chen S., Fryer J.D., Holtzman D.M., Hsu C.Y., Xu J. Matrix metalloproteinase-9 and spontaneous hemorrhage in an animal model of cerebral amyloid angiopathy. Ann. Neurol 2003, 54:379-382.
28. Lendon C.L., Thaker U., Harris J.M., McDonagh A.M., Lambert J.C., Chartier-Harlin M.C., Iwatsubo T., Pickering-Brown S.M., Mann D.M. The angiotensin 1-converting enzyme insertion (I)/deletion (D) polymorphism does not influence the extent of amyloid or tau pathology in patients with sporadic Alzheimer's disease. Neurosci. Lett 2002, 328:314-318.
29. Miners J.S., Ashby E., Van Helmond Z., Chalmers K.A., Palmer L.E., Love S., Kehoe P.G. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer's disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol. Appl. Neurobiol 2008, 34:181-193.
30. Miners S., Ashby E., Baig S., Harrison R., Tayler H., Speedy E., Prince J.A., Love S., Kehoe P.G. Angiotensin-converting enzyme levels and activity in Alzheimer's disease: differences in brain and CSF ACE and association with ACE1 genotypes. Am. J. Transl. Res 2009, 1:163-177.
31. Montaner J., Molina C.A., Monasterio J., Abilleira S., Arenillas J.F., Ribo M., Quintana M., Alvarez-Sabin J. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107:598-603.
32. Oba R., Igarashi A., Kamata M., Nagata K., Takano S., Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur. J. Neurosci 2005, 21:733-740.
33. Peck G., Smeeth L., Whittaker J., Casas J.P., Hingorani A., Sharma P. The genetics of primary haemorrhagic stroke, subarachnoid haemorrhage and ruptured intracranial aneurysms in adults. PLoS ONE 2008, 3:e3691.
34. Qureshi A.I., Tuhrim S., Broderick J.P., Batjer H.H., Hondo H., Hanley D.F. Spontaneous intracerebral hemorrhage. N. Engl. J. Med 2001, 344:1450-1460.
35. Ribo M., Montaner J., Molina C.A., Arenillas J.F., Santamarina E., Quintana M., Alvarez-Sabin J. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004, 35:2123-2127.
36. Rijn-Bikker P.C., Mairuhu G., van Montfrans G.A., Sijbrands E.J., Zwinderman A.H., Guchelaar H.J., Koopmans R.P. Genetic factors are relevant and independent determinants of antihypertensive drug effects in a multiracial population. Am. J. Hypertens 2009, 22:1295-1302.
37. Roher A.E., Kasunic T.C., Woods A.S., Cotter R.J., Ball M.J., Fridman R. Proteolysis of A beta peptide from Alzheimer disease brain by gelatinase A. Biochem. Biophys. Res. Commun 1994, 205:1755-1761.
38. Rozzini L., Chilovi B.V., Bertoletti E., Conti M., Del Rio I., Trabucchi M., Padovani A. Angiotensin converting enzyme (ACE) inhibitors modulate the rate of progression of amnestic mild cognitive impairment. Int. J. Geriatr. Psychiatry 2006, 21:550-555.
39. Sanchez-Valle R., Llado A., Ezquerra M., Rey M.J., Rami L., Molinuevo J.L. A novel mutation in the PSEN1 gene (L28 6P) associated with familial early-onset dementia of Alzheimer type and lobar haematomas. Eur. J. Neurol 2007, 14:1409-1412.
40. Slowik A., Borratynska A., Pera J., Betlej M., Dziedzic T., Krzyszkowski T., Czepko R., Figlewicz D.A., Szczudlik A. genotype of the angiotensin-converting enzyme gene increases the risk for subarachnoid hemorrhage from ruptured aneurysm. II. Stroke 2004, 35:1594-1597.
41. Slowik A., Turaj W., Dziedzic T., Haefele A., Pera J., Malecki M.T., Glodzik-Sobanska L., Szermer P., Figlewicz D.A., Szczudlik A. DD genotype of ACE gene is a risk factor for intracerebral hemorrhage. Neurology 2004, 63:359-361.
42. Suehiro T., Morita T., Inoue M., Kumon Y., Ikeda Y., Hashimoto K. Increased amount of the angiotensin-converting enzyme (ACE) mRNA originating from the ACE allele with deletion. Hum. Genet 2004, 115:91-96.
43. Thornton-Wells T.A., Moore J.H., Martin E.R., Pericak-Vance M.A., Haines J.L. Confronting complexity in late-onset Alzheimer disease: application of two-stage analysis approach addressing heterogeneity and epistasis. Genet. Epidemiol 2008, 32:187-203.
44. Toropygin I.Y., Kugaevskaya E.V., Mirgorodskaya O.A., Elisseeva Y.E., Kozmin Y.P., Popov I.A., Nikolaev E.N., Makarov A.A., Kozin S.A. The N-domain of angiotensin-converting enzyme specifically hydrolyzes the Arg-5-His-6 bond of Alzheimer's Abeta-(1-16) peptide and its isoAsp-7 analogue with different efficiency as evidenced by quantitative matrix-assisted laser desorption/ionization time-of-flight mass spectrometry. Rapid Commun. Mass Spectrom 2008, 22:231-239.
45. Tzourio C., Arima H., Harrap S., Anderson C., Godin O., Woodward M., Neal B., Bousser M.G., Chalmers J., Cambien F., MacMahon S. APOE genotype, ethnicity, and the risk of cerebral hemorrhage. Neurology 2008, 70:1322-1328.
46. Wahlund L.O., Barkhof F., Fazekas F., Bronge L., Augustin M., Sjogren M., Wallin A., Ader H., Leys D., Pantoni L., Pasquier F., Erkinjuntti T., Scheltens P. A new rating scale for age-related white matter changes applicable to MRI and CT. Stroke 2001, 32:1318-1322.
47. Woo D., Kaushal R., Chakraborty R., Woo J., Haverbusch M., Sekar P., Kissela B., Pancioli A., Jauch E., Kleindorfer D., Flaherty M., Schneider A., Khatri P., Sauerbeck L., Khoury J., Deka R., Broderick J. Association of apolipoprotein E4 and haplotypes of the apolipoprotein E gene with lobar intracerebral hemorrhage. Stroke 2005, 36:1874-1879.
48. Woo D., Sekar P., Chakraborty R., Haverbusch M.A., Flaherty M.L., Kissela B.M., Kleindorfer D., Schneider A., Khoury J., Sauerbeck L.R., Deka R., Broderick J.P. Genetic epidemiology of intracerebral hemorrhage. J. Stroke Cerebrovasc. Dis 2005, 14:239-243.
49. Yamada M. Cerebral amyloid angiopathy: an overview. Neuropathology 2000, 20:8-22.
50. Yamada M. Risk factors for cerebral amyloid angiopathy in the elderly. Ann. N Y Acad. Sci 2002, 977:37-44.
51. Yamada M. Cerebral amyloid angiopathy and gene polymorphisms. J. Neurol. Sci 2004, 226:41-44.
52. Yamada M., Sodeyama N., Itoh Y., Suematsu N., Otomo E., Matsushita M., Mizusawa H. Association of alpha1-antichymotrypsin polymorphism with cerebral amyloid angiopathy. Ann. Neurol 1998, 44:129-131.
53. Yoshida T., Ohno-Matsui K., Ichinose S., Sato T., Iwata N., Saido T.C., Hisatomi T., Mochizuki M., Morita I. The potential role of amyloid beta in the pathogenesis of age-related macular degeneration. J. Clin. Invest 2005, 115:2793-2800.
54. Zhu X., Bouzekri N., Southam L., Cooper R.S., Adeyemo A., McKenzie C.A., Luke A., Chen G., Elston R.C., Ward R. Linkage and association analysis of angiotensin I-converting enzyme (ACE)-gene polymorphisms with ACE concentration and blood pressure. Am. J. Hum. Genet 2001, 68:1139-1148.